The Food and Drug Administration is warning about overdoses on the popular diabetes drug semaglutide, causing adverse effects and hospitalizations, particularly from compounded forms.
Pharmacies have miscalculated the concentration of semaglutide in compounded drugs, leading patients to administer higher than intended doses, emphasizing the need for vigilance in dosing.
Patient errors, especially due to unfamiliarity with drawing medication and confusion in units of measurement while using compounded semaglutide, have been significant in dosing issues reported by the FDA.
Collection
[
|
...
]